2014 Fiscal Year Final Research Report
Inhibition of inducing multidrug resistance in human osteosarcoma cells by histone deacetylase inhibitor and DNA methylation inhibitor
| Project/Area Number |
24592247
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKASHO Keiji 兵庫医科大学, 医学部, 教授 (00217712)
YAMANEGI Koji 兵庫医科大学, 医学部, 講師 (00434944)
YAMADA Naoko 兵庫医科大学, 医学部, 講師 (10319858)
HATA Masaki 兵庫医科大学, 医学部, 研究生(研究員) (10446057)
OHYAMA Hideki 兵庫医科大学, 医学部, 非常勤講師 (90280685)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | 骨肉腫 / 薬剤耐性 / 非ステロイド系抗炎症剤 |
|---|
| Outline of Final Research Achievements |
We investigated that the combination of histone deacetylase (HDAC) inhibitor, hydralazine (DNA methylation inhibitor) and celecoxib (nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitor) inhibit inducing the expression of multidrug resistance (MDR) protein (MDR-1, MRP-1) in osteosarcoma cells without inhibiting cytotoxic sensitivity. The combination of HDAC inhibitor and celecoxib significantly inhibits cell-proliferation. This combination showed different reactions depending on the type of cells but generally inhibited. HDAC inhibitor alone increased MDR activity, however, combined with celecoxib reduced the activity depended on MDR-1 and MRP-1. These results suggest that combined treatment of HDAC inhibitor, hydralazine and celecoxib may be a useful for enhancing the effect of chemotherapy for osteosarcoma.
|
| Free Research Field |
実験病理学
|
